Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology.

1 Jul 2014

Non-Hodgkin lymphoma subgroups found to have different survival rates

A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.

27 Jun 2014

Researchers identify two oncogenes that drive the development of medulloblastoma

A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute, UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children.

23 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.

31 May 2014

MRI detects invasive breast tumours at very early stages in survivors of childhood Hodgkin lymphoma

The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma (HL), who are at increased risk because they received chest radiation, shows that magnetic-resonance imaging (MRI) detected invasive breast tumours at very early stages, when cure rates are expected to be excellent.

29 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Researchers discover how of EBV virus takes over human cells gene regulating machinery

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself.

10 Apr 2014

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma.

10 Apr 2014

University of Montreal scientists discover molecular details of kissing disease virus attacks

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself.

10 Apr 2014

Menopausal hormone therapy may lower risk of B-cell non-Hodgkin lymphoma

Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.

8 Apr 2014

Helium ion radiotherapy provides hope for improved, accurate radiation treatment for young cancer patients

For the first time, researchers have been able to demonstrate that the use of helium ions in radiation therapy could provide accurate treatment to tumours while helping to spare healthy organs.

7 Apr 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year.

29 Mar 2014

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.

28 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

HIV-positive people with early-stage cancer less likely to get cancer treatment

Non-Hodgkin lymphoma subgroups found to have different survival rates

Researchers identify two oncogenes that drive the development of medulloblastoma

Cancer drug offers protection against thrombosis

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

MRI detects invasive breast tumours at very early stages in survivors of childhood Hodgkin lymphoma

Alligator Bioscience acquires rights to drug development candidate ADC-1013

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Researchers discover how of EBV virus takes over human cells gene regulating machinery

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

University of Montreal scientists discover molecular details of kissing disease virus attacks

Menopausal hormone therapy may lower risk of B-cell non-Hodgkin lymphoma

Helium ion radiotherapy provides hope for improved, accurate radiation treatment for young cancer patients

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Einstein faculty members present recent research at AACR Annual Meeting

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

A pill may provide hope to relapsed leukemia and lymphoma patients

Antares Pharma announces launch of OTREXUP to Dermatologists

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in